Clinical characteristics of patients: group B (remission consolidation)
| . | . | All patients . | FL . | MCL . | LL . |
|---|---|---|---|---|---|
| n | 21 | 14 | 6 | 1 | |
| Median (range) age | years | 54 (29-70) | 51 (29-70) | 56 (44-64) | 37 |
| Stage | IIA* | 1* | 1* | 0 | 0 |
| IIIA | 6 | 5 | 1 | 0 | |
| IIIB | 2 | 2 | 0 | 0 | |
| IVA | 10 | 5 | 5 | 1 | |
| IVB | 2 | 1 | 1 | 0 | |
| Risk score: n | IPI 1/5: 10 | FLIPI 1/5: 4 | MIPI 5-6: 3 | IPI 2/5: 1 | |
| IPI 2-3/5: 9 | FLIPI 2/5: 7 | MIPI 6-7: 3 | |||
| IPI 4-5/5: 2 | FLIPI 3-4/5: 3 | ||||
| Last systemic therapy | CHOP | 2 | 2 | 0 | 0 |
| R-CHOP | 6 | 6 | 0 | 0 | |
| F | 1 | 0 | 1 | 0 | |
| FC | 2 | 1 | 0 | 1 | |
| FC-R | 2 | 2 | 0 | 0 | |
| Auto-SCT | 5 | 0 | 5 | 0 | |
| R mono | 2 | 2 | 0 | 0 | |
| Chloramb | 1 | 1 | 0 | 0 | |
| Remission status | First CR | 11 | 6 | 5 | 0 |
| First PR | 3 | 1 | 1 | 1 | |
| Second CR | 2 | 2 | 0 | 0 | |
| Second PR | 4 | 4 | 0 | 0 | |
| Fifth PR | 1 | 1 | 0 | 0 | |
| Median (range) time | months | 5 (1-21) | 6 {1-21) | 3 (3-15) | 1 |
| end chemotherapy to first vaccination | |||||
| FcγRIIIa genotype | 158FF | 11 | 8 | 2 | 1 |
| 158FV | 8 | 5 | 3 | 0 | |
| 158VV | 2 | 1 | 1 | 0 |
| . | . | All patients . | FL . | MCL . | LL . |
|---|---|---|---|---|---|
| n | 21 | 14 | 6 | 1 | |
| Median (range) age | years | 54 (29-70) | 51 (29-70) | 56 (44-64) | 37 |
| Stage | IIA* | 1* | 1* | 0 | 0 |
| IIIA | 6 | 5 | 1 | 0 | |
| IIIB | 2 | 2 | 0 | 0 | |
| IVA | 10 | 5 | 5 | 1 | |
| IVB | 2 | 1 | 1 | 0 | |
| Risk score: n | IPI 1/5: 10 | FLIPI 1/5: 4 | MIPI 5-6: 3 | IPI 2/5: 1 | |
| IPI 2-3/5: 9 | FLIPI 2/5: 7 | MIPI 6-7: 3 | |||
| IPI 4-5/5: 2 | FLIPI 3-4/5: 3 | ||||
| Last systemic therapy | CHOP | 2 | 2 | 0 | 0 |
| R-CHOP | 6 | 6 | 0 | 0 | |
| F | 1 | 0 | 1 | 0 | |
| FC | 2 | 1 | 0 | 1 | |
| FC-R | 2 | 2 | 0 | 0 | |
| Auto-SCT | 5 | 0 | 5 | 0 | |
| R mono | 2 | 2 | 0 | 0 | |
| Chloramb | 1 | 1 | 0 | 0 | |
| Remission status | First CR | 11 | 6 | 5 | 0 |
| First PR | 3 | 1 | 1 | 1 | |
| Second CR | 2 | 2 | 0 | 0 | |
| Second PR | 4 | 4 | 0 | 0 | |
| Fifth PR | 1 | 1 | 0 | 0 | |
| Median (range) time | months | 5 (1-21) | 6 {1-21) | 3 (3-15) | 1 |
| end chemotherapy to first vaccination | |||||
| FcγRIIIa genotype | 158FF | 11 | 8 | 2 | 1 |
| 158FV | 8 | 5 | 3 | 0 | |
| 158VV | 2 | 1 | 1 | 0 |
IPI indicates International Prognostic Index; FLIPI, Follicular Lymphoma International Prognostic Index; MIPI, Mantle Cell Lymphoma International Prognostic Index; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CHOP, CHOP and rituximab; F, fludarabine; FC, fludarabine and cyclophosphamide; FC-R, FC and rituximab; Auto-SCT, high-dose chemotherapy and autologous stem cell transplantation; R mono, rituximab monotherapy; and Chloramb, chlorambucil.
One FL patient with stage IIA was deemed unsuitable for radiation therapy because of bulky intra-abdominal disease. She was treated as a stage IIIA patient with chemotherapy and was therefore included into this trial.